Abemaciclib in Breast Cancer Treatment
Medical Supporter — إشعار معلوماتي
هذه المقالة ملخص لمعلومات طبية دولية وليست نصيحة طبية، ولا يمكن أن تحل محل تشخيص طبيبك المعالج أو خطة العلاج. المعلومات المعروضة مجمّعة من منشورات عامة وبيانات رسمية لكبرى المؤسسات الطبية اليابانية؛ وتختلف ملاءمة ونتائج أي علاج من مريض لآخر ويجب أن يقيّمها طبيب مؤهل لكل حالة على حدة.
- April 26, 2017
- Reading time: 1 minute
Eli Lilly and Company announced significant findings regarding its investigational agent, Abemaciclib, for the treatment of HER2-negative advanced breast cancer. An interim analysis of the Phase 3 MONARCH 3 study demonstrated that the combination of Abemaciclib (a CDK4/6 inhibitor) with an aromatase inhibitor (CYP19 inhibitor) significantly prolonged progression-free survival (PFS) compared to aromatase inhibitor monotherapy.
The MONARCH 3 trial reached its primary endpoint of improved PFS. Additionally, the results showed improvements in objective response rates (ORR) in the combination arm. Detailed findings from this clinical trial are expected to be presented later this year.
MONARCH 3 is a global, double-blind, placebo-controlled Phase 3 clinical trial enrolling 493 postmenopausal women with HER2-negative advanced or metastatic breast cancer who have not received prior systemic therapy for their advanced disease. The study evaluates the efficacy and safety of Abemaciclib (150 mg twice daily) in combination with either Anastrozole (1 mg daily) or Letrozole (2.5 mg daily), compared to an aromatase inhibitor plus placebo.
The secondary endpoints include overall response rate, overall survival, and safety. Consistent with previous clinical evaluations of Abemaciclib, the most frequently reported adverse events include diarrhea, fatigue, nausea, and neutropenia.
Source: Eli Lilly and Company Investor Relations News.
Breast Cancer
- Clinical Trial Medications
- (Lung Cancer) Phase II results for Topotecan and Topotecan + Berzosertib combination.
- (Lung Cancer) Efficacy of Enhertu in HER2-mutant non-small cell lung cancer (NSCLC).
- (Lung Cancer) Clinical outcomes of anti-B7-H3 antibody-drug conjugate DS-7300.
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
هل تفكر في تلقّي العلاج في اليابان؟ هل تحتاج إلى معلومات ومساعدة؟
نساعدك في تنظيم المعلومات اللازمة للسفر الطبي إلى اليابان، والتواصل مع المؤسسات الطبية اليابانية، وترتيب استشارة رأي ثانٍ.الاستشارة الأولى مجانية؛ سيساعدك المستشار على توضيح الخطوات التالية.
Figure 1
Figure 2
Figure 3
Figure 4